JANUARY 16, 2017

Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates



Fedora co-signs the  Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance



NOVEMBER 30, 2015

Fedora Pharmaceuticals Receives Alberta Life Sciences "Company of the Year" Award



Scientific Advisory Board

Dr. Karen Bush

 Karen Bush

Dr. Bush, with a Ph.D. in biochemistry from Indiana University, began her work on β-lactamases and β-lactamase inhibitors at the Squibb Institute for Medical Research in 1977, and continued working in anti-infective research at Bristol-Myers Squibb, Lederle (now part of Pfizer), Astra Zeneca and Johnson & Johnson until 2009.

During her pharmaceutical career Dr. Bush worked on the research teams that discovered and developed aztreonam, Zosyn® (piperacillin-tazobactam), levofloxacin, doripenem, ceftobiprole and the influenza drug peramivir. She also led a microbiology research team that was responsible for the discovery and early development of novel ketolides, oxazolidinones and fluoroquinolones.

Dr. Bush is currently an Adjunct Professor in the Biology Department and the Biochemistry Department at Indiana University where she teaches in the graduate biotechnology program. She is a Fellow of the American Academy of Microbiology, an Advisor for the Clinical and Laboratory Standards Institute, a past editor of the journal, Antimicrobial Agents & Chemotherapy and a reviewer for many microbiology journals and NIH study sections.